Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib Plus Venetoclax for Relapsed/Refractory DLBCL
NCT04572763Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of copanlisib and venetoclax in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 1 year and Overall Response Rate at 28 days. Started Sep 2021; status: active, not recruiting.
02
Drugs
copanlisibvenetoclax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04572763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572763.